恩度联合TP方案治疗中晚期非小细胞肺癌的临床观察

Clincal observation of endu combinated TP plan on nonsmall-cell lung cancer

目的评价恩度联合TP方案治疗中晚期非小细胞肺癌的临床疗效及安全性。方法选择中晚期非小细胞肺癌住院患者55例,随机分为对照组及观察组。两组均给予常规TP方案化疗,观察组另给予恩度治疗,两周期后评价疗效及毒副反应。结果观察组总有效率为57.1%,对照组总有效率为29.6%,治疗组总有效率高于对照组(P<0.05)。两组间毒副反应发生率差异无统计学意义(P>0.05)。结论恩度联合TP方案化疗治疗中晚期非小细胞肺癌是一种安全有效的方案,值得在临床上推广应用。

Objective To eveluate the safety and curative effec of endu eombinated TP plan on nonsmall - cell lung caneer（NSCLC）. Methods 55 eases of patients with metaphase and late NSCLC were selected and randomly divided into observation groups and control groups, all patients received chemotherapeuties with rip plan, pattients in observation groups received endu treatment in addition, after two groups, clinical curative effect and toxicity reaction was contrasted. Results Clinical effective power was 57.1% in observation groups and was 29.6% in control groups, clinical effective power was higher in observation groups than in control groups （ P 〈 0. 05 ）. incidence rate of toxicity reaction was identical between observation groups and control groups （ P 〉 0, 05 ）. Conclusion Endu combinated TP plan on nonsmall - cell lung cancer was safe and effective, was valuable for generalization application in clinic.